Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.

Jimeno A, Moore KN, Gordon M, Chugh R, Diamond JR, Aljumaily R, Mendelson D, Kapoun AM, Xu L, Stagg R, Smith DC.

Invest New Drugs. 2018 Sep 19. doi: 10.1007/s10637-018-0665-y. [Epub ahead of print]

PMID:
30229512
2.

A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study.

Boardman CH, Brady WE, Dizon DS, Kunos CA, Moore KN, Zanotti KM, Matthews C, Cosin JA, Aghajanian C, Fracasso PM.

Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31095-3. doi: 10.1016/j.ygyno.2018.08.006. [Epub ahead of print]

PMID:
30174176
3.

Reuse of intermittent catheters: a qualitative study of IC users' perspectives.

Avery M, Prieto J, Okamoto I, Cullen S, Clancy B, Moore KN, Macaulay M, Fader M.

BMJ Open. 2018 Aug 17;8(8):e021554. doi: 10.1136/bmjopen-2018-021554.

4.

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.

Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ.

Gynecol Oncol. 2018 Aug 6. pii: S0090-8258(18)31081-3. doi: 10.1016/j.ygyno.2018.07.017. [Epub ahead of print]

5.

First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors.

Moore KN, Bendell JC, LoRusso PM, Olszanski AJ, Zwick-Wallasch E, Jansen M, Vandell AG, Senaldi G.

Invest New Drugs. 2018 Jul 28. doi: 10.1007/s10637-018-0646-1. [Epub ahead of print]

PMID:
30056611
6.

Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer.

Buechel M, Dey A, Dwivedi SKD, Crim A, Ding K, Zhang R, Mukherjee P, Moore KN, Cao L, Branstrom A, Weetall M, Baird J, Bhattacharya R.

Mol Cancer Ther. 2018 Jul 19. doi: 10.1158/1535-7163.MCT-17-1192. [Epub ahead of print]

PMID:
30026381
7.

Niraparib for the treatment of ovarian cancer.

Essel KG, Moore KN.

Expert Rev Anticancer Ther. 2018 Aug;18(8):727-733. doi: 10.1080/14737140.2018.1490180. Epub 2018 Jul 2.

PMID:
29911447
8.

Delayed fear extinction in individuals with insomnia disorder.

Seo J, Moore KN, Gazecki S, Bottary RM, Milad MR, Song H, Pace-Schott EF.

Sleep. 2018 Aug 1;41(8). doi: 10.1093/sleep/zsy095.

PMID:
29860407
9.

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Grisham RN, Moore KN, Gordon MS, Harb W, Cody G, Halpenny DF, Makker V, Aghajanian CA.

Clin Cancer Res. 2018 May 29. doi: 10.1158/1078-0432.CCR-18-0494. [Epub ahead of print]

PMID:
29844129
10.

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.

Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC.

Ann Oncol. 2018 Feb 23. doi: 10.1093/annonc/mdy076. [Epub ahead of print]

PMID:
29788155
11.

Clinical trial methodology in rare gynecologic tumor research: Strategies for success.

Brown J, Naumann RW, Brady WE, Coleman RL, Moore KN, Gershenson DM.

Gynecol Oncol. 2018 Jun;149(3):605-611. doi: 10.1016/j.ygyno.2018.04.008. Epub 2018 Apr 24. Review.

PMID:
29699802
12.

Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.

McClurg D, Bugge C, Elders A, Irshad T, Hagen S, Moore KN, Buckley B, Fader M.

Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722. [Epub ahead of print]

PMID:
29683042
13.

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.

Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, Wacheck V, Moore KN.

Clin Cancer Res. 2018 Jul 15;24(14):3253-3262. doi: 10.1158/1078-0432.CCR-17-3421. Epub 2018 Apr 10.

PMID:
29636360
14.

Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough.

Dockery LE, Motwani A, Ding K, Doescher M, Dvorak JD, Moore KN, Holman LL.

Gynecol Oncol. 2018 Apr;149(1):89-92. doi: 10.1016/j.ygyno.2017.10.023.

PMID:
29605056
15.

Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes.

Buechel M, McGinnis A, Vesely SK, Wade KS, Moore KN, Gunderson CC.

Gynecol Oncol. 2018 Apr;149(1):28-32. doi: 10.1016/j.ygyno.2017.11.021.

PMID:
29605046
16.

Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.

Moore KN, Birrer MJ.

Oncologist. 2018 Jun;23(6):697-703. doi: 10.1634/theoncologist.2017-0485. Epub 2018 Mar 28. Review.

PMID:
29593098
17.

Development of a Quantitative LC-MS-MS Assay for Codeine, Morphine, 6-Acetylmorphine, Hydrocodone, Hydromorphone, Oxycodone and Oxymorphone in Neat Oral Fluid.

Grabenauer M, Moore KN, Bynum ND, White RM, Mitchell JM, Hayes ED, Flegel R.

J Anal Toxicol. 2018 Jul 1;42(6):392-399. doi: 10.1093/jat/bky021.

PMID:
29554298
18.

An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers.

Castellano T, Moore KN, Holman LL.

Clin Ther. 2018 Mar;40(3):372-388. doi: 10.1016/j.clinthera.2018.01.005. Epub 2018 Mar 9. Review.

PMID:
29530456
19.

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.

Moore KN, Bauer TM, Falchook GS, Chowdhury S, Patel C, Neuwirth R, Enke A, Zohren F, Patel MR.

ESMO Open. 2018 Feb 1;3(2):e000291. doi: 10.1136/esmoopen-2017-000291. eCollection 2018.

20.

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.

Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier P, Malek K, Birrer MJ.

Future Oncol. 2018 Jul;14(17):1669-1678. doi: 10.2217/fon-2017-0646. Epub 2018 Feb 9.

21.

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.

Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, Trask P, Lin K, Schuth E, Vaze A, Choi Y, Marsters JC, Maslyar DJ, Lemahieu V, Wang Y, Humke EW, Liu JF.

Ann Oncol. 2018 Apr 1;29(4):917-923. doi: 10.1093/annonc/mdy023.

PMID:
29401246
22.

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.

Moore KN, Mirza MR, Matulonis UA.

Gynecol Oncol. 2018 Apr;149(1):214-220. doi: 10.1016/j.ygyno.2018.01.011. Epub 2018 Feb 4. Review.

PMID:
29397193
23.

Management of the toxicities of common targeted therapeutics for gynecologic cancers.

Gunderson CC, Matulonis U, Moore KN.

Gynecol Oncol. 2018 Mar;148(3):591-600. doi: 10.1016/j.ygyno.2018.01.010. Epub 2018 Feb 1. Review.

PMID:
29395304
24.

Defining and mitigating the challenges of an older and obese population in minimally invasive gynecologic cancer surgery.

Hagemann AR, McCourt CK, Varaday SS, Moore KN.

Gynecol Oncol. 2018 Mar;148(3):601-608. doi: 10.1016/j.ygyno.2017.12.020. Epub 2018 Jan 10. Review.

PMID:
29329881
25.

Detection and quantification of codeine-6-glucuronide, hydromorphone-3-glucuronide, oxymorphone-3-glucuronide, morphine 3-glucuronide and morphine-6-glucuronide in human hair from opioid users by LC-MS-MS.

Grabenauer M, Bynum ND, Moore KN, White RM, Mitchell JM, Hayes ED, Flegel R.

J Anal Toxicol. 2018 Mar 1;42(2):115-125. doi: 10.1093/jat/bkx086.

PMID:
29186453
26.

The redesigned Forensic Research/Reference on Genetics-knowledge base, FROG-kb.

Kidd KK, Soundararajan U, Rajeevan H, Pakstis AJ, Moore KN, Ropero-Miller JD.

Forensic Sci Int Genet. 2018 Mar;33:33-37. doi: 10.1016/j.fsigen.2017.11.009. Epub 2017 Nov 14.

27.

Patterns of Marijuana Use in a 6-Month Pain Management Sample in the United States.

Smiley-McDonald HM, Moore KN, Heller DC, Ropero-Miller JD, McIntire GL, Wallace FN.

Subst Abuse. 2017 Aug 16;11:1178221817724783. doi: 10.1177/1178221817724783. eCollection 2017. Review.

28.

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ.

Future Oncol. 2018 Jan;14(2):123-136. doi: 10.2217/fon-2017-0379. Epub 2017 Nov 3. Review.

29.

Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.

Dockery LE, Tew WP, Ding K, Moore KN.

Gynecol Oncol. 2017 Dec;147(3):509-513. doi: 10.1016/j.ygyno.2017.10.007. Epub 2017 Oct 14.

PMID:
29037805
30.

Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study.

Bishop EA, Java JJ, Moore KN, Spirtos NM, Pearl ML, Zivanovic O, Kushner DM, Backes F, Hamilton CA, Geller MA, Hurteau J, Mathews C, Wenham RM, Ramirez PT, Zweizig S, Walker JL.

Am J Obstet Gynecol. 2018 Jan;218(1):109.e1-109.e11. doi: 10.1016/j.ajog.2017.09.026. Epub 2017 Oct 14.

PMID:
29037481
31.

Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ; Ovarian Cancer Association Consortium, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ.

Gynecol Oncol. 2017 Nov;147(2):396-401. doi: 10.1016/j.ygyno.2017.08.024. Epub 2017 Sep 19.

32.

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.

Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ.

Gynecol Oncol. 2017 Nov;147(2):402-407. doi: 10.1016/j.ygyno.2017.08.015. Epub 2017 Aug 24.

33.
34.

WITHDRAWN: Intermittent catheterisation for long-term bladder management.

Prieto J, Murphy CL, Moore KN, Fader M.

Cochrane Database Syst Rev. 2017 Aug 8;8:CD006008. doi: 10.1002/14651858.CD006008.pub4. Review.

PMID:
28796279
35.

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.

Dockery LE, Gunderson CC, Moore KN.

Onco Targets Ther. 2017 Jun 19;10:3029-3037. doi: 10.2147/OTT.S114714. eCollection 2017. Review.

36.

Effects of feedback and test practice on recollection and retrieval monitoring: comparing first graders, third graders, and adults.

Moore KN, Lampinen JM, Gallo DA, Bridges AJ.

Memory. 2018 Apr;26(4):424-438. doi: 10.1080/09658211.2017.1360356. Epub 2017 Aug 4.

PMID:
28774228
37.

Factors influencing clinical trial enrollment among ovarian cancer patients.

Greenwade MM, Moore KN, Gillen JM, Ding K, Rowland MR, Crim AK, Kleis B, Gunderson CC.

Gynecol Oncol. 2017 Sep;146(3):465-469. doi: 10.1016/j.ygyno.2017.06.035. Epub 2017 Jul 6.

PMID:
28689668
38.

Identification of Eight Synthetic Cannabinoids, Including 5F-AKB48 in Seized Herbal Products Using DART-TOF-MS and LC-QTOF-MS as Nontargeted Screening Methods.

Moore KN, Garvin D, Thomas BF, Grabenauer M.

J Forensic Sci. 2017 Sep;62(5):1151-1158. doi: 10.1111/1556-4029.13367. Epub 2017 Jun 9.

PMID:
28597943
39.

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.

Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ.

Cancer. 2017 Aug 15;123(16):3080-3087. doi: 10.1002/cncr.30736. Epub 2017 Apr 25.

40.

Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2.

Bishop EA, Java JJ, Moore KN, Walker JL.

Int J Gynecol Cancer. 2017 May;27(4):730-737. doi: 10.1097/IGC.0000000000000947.

41.

Sparse feature selection for classification and prediction of metastasis in endometrial cancer.

Ahsen ME, Boren TP, Singh NK, Misganaw B, Mutch DG, Moore KN, Backes FJ, McCourt CK, Lea JS, Miller DS, White MA, Vidyasagar M.

BMC Genomics. 2017 Mar 27;18(Suppl 3):233. doi: 10.1186/s12864-017-3604-y.

42.

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS.

Gynecol Oncol. 2017 May;145(2):236-242. doi: 10.1016/j.ygyno.2017.03.013. Epub 2017 Mar 22.

43.

Children's Use of Memory Editing Strategies to Reject Source Misinformation.

Moore KN, Lampinen JM, Gallo DA, Adams EJ, Bridges AJ.

Child Dev. 2018 Jan;89(1):219-234. doi: 10.1111/cdev.12716. Epub 2017 Feb 15.

PMID:
28197997
44.

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.

McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010.

PMID:
28119296
45.

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ.

J Clin Oncol. 2017 Apr 1;35(10):1112-1118. doi: 10.1200/JCO.2016.69.9538. Epub 2016 Dec 28.

46.

Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.

Prendergast EN, Holzapfel M, Mueller JJ, Leitao MM Jr, Gunderson CC, Moore KN, Erickson BK, Leath CA 3rd, Diaz Moore ES, Cohen JG, Walsh CS.

Gynecol Oncol. 2017 Feb;144(2):274-278. doi: 10.1016/j.ygyno.2016.12.004. Epub 2016 Dec 12.

47.

Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial.

Thomas ED, Nugent EK, MacAllister MC, Moxley KM, Landrum L, L Walker J, McMeekin DS, Mannel RS, McGwin G, Moore KN.

Gynecol Oncol. 2017 Jan;144(1):193-199. doi: 10.1016/j.ygyno.2016.11.008. Epub 2016 Nov 9.

PMID:
27836205
48.

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.

Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, Kahn R, Wang Y, Wood K, Darbonne WC, Lackner MR, Kelley SK, Lu X, Choi YJ, Maslyar D, Humke EW, Burris HA.

Ann Oncol. 2016 Nov;27(11):2124-2130.

PMID:
27793850
49.

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.

Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB.

Gynecol Oncol. 2016 Nov;143(2):294-301. doi: 10.1016/j.ygyno.2016.08.317. Epub 2016 Aug 17.

50.

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI.

Gynecol Oncol. 2016 Oct;143(1):3-15. doi: 10.1016/j.ygyno.2016.05.022. Epub 2016 Aug 8.

Supplemental Content

Loading ...
Support Center